Document is current

Article History

Received: 21 March 2025

Accepted: 29 April 2025

First Online: 9 June 2025

Compliance with ethical standards

:

: A. Christoforidis has received consulting fees, honoraria and travel support from Sandoz, Pfizer, Novo Nordisk and Eli Lilly. F. E. Karachaliou has served as consultant, advisor, and has received honoraria and travel support from Pfizer, Novo Nordisk, Sandoz and Serono. A. Galli-Tsinopoulou has served as consultant, advisor, and has received honoraria and travel support from Astra Zeneca, Novo Nordisk, Biomarin, Genesis and Pfizer. D. Chrysis has received grants and travel support from Pfizer, Novo Nordisk, Merck and Pfizer. C. Kanaka-Gantenbein has served as consultant, advisor, and has received grants, honoraria and travel support from Novo Nordisk, BioMarin, Genesis, Sandoz, Eli Lilly and Pfizer. Also, C. Kanaka-Gantenbein is the vice president of the Hellenic Society for Pediatric and Adolescent Endocrinology. E. A. Vlachopapadopoulou has served as consultant, advisor, and has received grants, honoraria and travel support from Novo Nordisk, Amgen, Sandoz, Pfizer, BioMarin and Ascendis. I. Skiadas, O. Zisimopoulou, E. Baxevanidi, D. Tsilakis, and A. Poimenidou are employees of Pfizer and may hold stock or stock options.

: The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE). The study protocol, protocol amendments, and informed consent forms were approved by the institutional review board (IRB)/independent ethics committee (IEC) of the participating centres.

: Signed informed consent was obtained from patients’ guardians as well as patient’s assent (written or verbal depending on patient ‘s age) as applicable before any study procedures commenced.